Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Lancet Oncol ; 23(7): 910-918, 2022 07.
Article in English | MEDLINE | ID: mdl-35714666

ABSTRACT

BACKGROUND: Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. METHODS: In this single-arm, multicentre, phase 2b study conducted at eight health-care centres in the USA, we recruited men aged 50 years and older with unilateral, MRI-visible, primary, intermediate-risk, previously untreated prostate adenocarcinoma (prostate-specific antigen ≤20 ng/mL, grade group 2 or 3; tumour classification ≤T2) confirmed on combined biopsy (combining MRI-targeted and systematic biopsies). MRI-guided focused ultrasound energy, sequentially titrated to temperatures sufficient for tissue ablation (about 60-70°C), was delivered to the index lesion and a planned margin of 5 mm or more of normal tissue, using real-time magnetic resonance thermometry for intraoperative monitoring. Co-primary outcomes were oncological outcomes (absence of grade group 2 and higher cancer in the treated area at 6-month and 24-month combined biopsy; when 24-month biopsy data were not available and grade group 2 or higher cancer had occurred in the treated area at 6 months, the 6-month biopsy results were included in the final analysis) and safety (adverse events up to 24 months) in all patients enrolled in the study. This study is registered with ClinicalTrials.gov, NCT01657942, and is no longer recruiting. FINDINGS: Between May 4, 2017, and Dec 21, 2018, we assessed 194 patients for eligibility and treated 101 patients with MRI-guided focused ultrasound. Median age was 63 years (IQR 58-67) and median concentration of prostate-specific antigen was 5·7 ng/mL (IQR 4·2-7·5). Most cancers were grade group 2 (79 [78%] of 101). At 24 months, 78 (88% [95% CI 79-94]) of 89 men had no evidence of grade group 2 or higher prostate cancer in the treated area. No grade 4 or grade 5 treatment-related adverse events were reported, and only one grade 3 adverse event (urinary tract infection) was reported. There were no treatment-related deaths. INTERPRETATION: 24-month biopsy outcomes show that MRI-guided focused ultrasound focal therapy is safe and effectively treats grade group 2 or 3 prostate cancer. These results support focal therapy for select patients and its use in comparative trials to determine if a tissue-preserving approach is effective in delaying or eliminating the need for radical whole-gland treatment in the long term. FUNDING: Insightec and the National Cancer Institute.


Subject(s)
Prostate-Specific Antigen , Prostatic Neoplasms , Aged , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Prospective Studies , Prostate/pathology , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/pathology , Prostatic Neoplasms/therapy
2.
Clin Imaging ; 88: 33-35, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35605566

ABSTRACT

Uterine Fibroid Embolization is an effective method of treating uterine fibroids as an alternative to surgery. Positional changes of the uterus secondary to pregnancy, pelvic surgery, urinary retention, endometriosis and fibroids have all been reported, however, no literature has specifically described the uterus incidentally changing position during uterine fibroid embolization. We present a unique case of uterine reorientation during a uterine fibroid embolization procedure.


Subject(s)
Embolization, Therapeutic , Leiomyoma , Uterine Neoplasms , Embolization, Therapeutic/methods , Female , Humans , Leiomyoma/diagnostic imaging , Leiomyoma/therapy , Pregnancy , Treatment Outcome , Uterine Neoplasms/diagnostic imaging , Uterine Neoplasms/therapy , Uterus/diagnostic imaging
3.
Clin Imaging ; 80: 190-192, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34340200

ABSTRACT

Post-operative hematoma is a common surgical complication, often treated conservatively. However, persistent, recurrent or symptomatic hematomas may require percutaneous or surgical drainage. The authors present two cases of persistent post-surgical hematomas which were successfully evacuated in a single-setting using a percutaneous mechanical thrombectomy system.


Subject(s)
Abdominal Wall , Abdominal Wall/diagnostic imaging , Abdominal Wall/surgery , Catheters , Hematoma/diagnostic imaging , Hematoma/etiology , Hematoma/surgery , Humans , Thrombectomy , Treatment Outcome
4.
Clin Imaging ; 77: 111-116, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33667943

ABSTRACT

Uterine artery embolization (UAE) for symptomatic uterine fibroids is accompanied by transcervical fibroid expulsion in 3-15% of cases. It can be a source of significant patient distress, may require reintervention for removal, and is the most common reason for hospital readmission following UAE. Conversely, the success of hysteroscopic resection decreases with increasing fibroid size while the risk of complications increases. Because certain fibroid features identifiable on preoperative imaging predict need for eventual hysteroscopic resection, it is possible to prospectively identify such patients and employ an alternative management strategy. We present such an approach, illustrated in the case of a woman with a pedunculated broad-based uterine fibroid successfully managed via combination UAE and immediate hysteroscopic resection.


Subject(s)
Embolization, Therapeutic , Leiomyoma , Uterine Artery Embolization , Uterine Neoplasms , Female , Humans , Leiomyoma/diagnostic imaging , Leiomyoma/surgery , Patient Care , Treatment Outcome , Uterine Neoplasms/diagnostic imaging , Uterine Neoplasms/surgery
5.
Clin Imaging ; 61: 1-3, 2020 May.
Article in English | MEDLINE | ID: mdl-31945687

ABSTRACT

Uterine leiomyomas are the most common solid pelvic tumors in pre-menopausal women and typically present with abnormal uterine bleeding and/or symptoms of mass effect. A potential consequence of the space-occupying nature of these lesions is the decreased sensitivity for the detection of adjacent pelvic pathology, which can be particularly problematic given the overlap in symptoms between fibroids and other pelvic disease. We present the case of a woman with a large uterine fibroid who had multiple imaging evaluations before undergoing uterine fibroid embolization and on immediate follow-up sonography was discovered to have early-stage bladder cancer.


Subject(s)
Urinary Bladder Neoplasms/diagnostic imaging , Embolization, Therapeutic/methods , Female , Humans , Leiomyoma/diagnostic imaging , Leiomyoma/pathology , Middle Aged , Rare Diseases , Ultrasonography , Uterine Neoplasms/diagnostic imaging , Uterine Neoplasms/pathology
7.
Article in English | MEDLINE | ID: mdl-31592503

ABSTRACT

PURPOSE: We developed a precision medicine program for patients with advanced cancer using integrative whole-exome sequencing and transcriptome analysis. PATIENTS AND METHODS: Five hundred fifteen patients with locally advanced/metastatic solid tumors were prospectively enrolled, and paired tumor/normal sequencing was performed. Seven hundred fifty-nine tumors from 515 patients were evaluated. RESULTS: Most frequent tumor types were prostate (19.4%), brain (16.5%), bladder (15.4%), and kidney cancer (9.2%). Most frequently altered genes were TP53 (33%), CDKN2A (11%), APC (10%), KTM2D (8%), PTEN (8%), and BRCA2 (8%). Pathogenic germline alterations were present in 10.7% of patients, most frequently CHEK2 (1.9%), BRCA1 (1.5%), BRCA2 (1.5%), and MSH6 (1.4%). Novel gene fusions were identified, including a RBM47-CDK12 fusion in a metastatic prostate cancer sample. The rate of clinically relevant alterations was 39% by whole-exome sequencing, which was improved by 16% by adding RNA sequencing. In patients with more than one sequenced tumor sample (n = 146), 84.62% of actionable mutations were concordant. CONCLUSION: Integrative analysis may uncover informative alterations for an advanced pan-cancer patient population. These alterations are consistent in spatially and temporally heterogeneous samples.

8.
Clin Imaging ; 58: 105-107, 2019.
Article in English | MEDLINE | ID: mdl-31284177

ABSTRACT

Endometrioma superinfection is uncommon and poorly described in the literature. This rarity has precluded agreement on optimal management, with most authors treating these lesions as endometriomas rather than abscesses and thus recommending laparoscopic or open cystectomy or oophorectomy. We present a minimally-invasive alternative, illustrated in the case of an infected endometrioma which was successfully managed via image-guided percutaneous drainage.


Subject(s)
Bacterial Infections/surgery , Drainage/methods , Endometriosis/microbiology , Adult , Female , Firmicutes/isolation & purification , Humans
10.
Cardiovasc Intervent Radiol ; 42(2): 308-312, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30420997

ABSTRACT

Inferior vena cava agenesis is an uncommon condition usually attributed to embryologic dysgenesis. When symptomatic, unprovoked deep venous thrombosis and/or lower extremity venous congestion are the most frequent manifestations. Its rarity has precluded consensus regarding appropriate management. Symptomatic chronic venous congestion requires surgical construction of auxiliary venous pathways, which may involve substantial morbidity, prolonged recovery and extensive scarring. We report successful minimally invasive management via percutaneous endovascular orthotopic inferior vena cava construction in a pediatric patient, thereby obviating the need for surgery and its associated morbidity. LEVEL OF EVIDENCE: Level IV, case study.


Subject(s)
Endovascular Procedures/methods , Minimally Invasive Surgical Procedures/methods , Vena Cava, Inferior/abnormalities , Vena Cava, Inferior/surgery , Adolescent , Diagnosis, Differential , Fluoroscopy , Humans , Magnetic Resonance Imaging , Male , Treatment Outcome , Ultrasonography , Vena Cava, Inferior/diagnostic imaging
11.
Cancer ; 124(5): 1008-1015, 2018 03 01.
Article in English | MEDLINE | ID: mdl-29266381

ABSTRACT

BACKGROUND: Metastatic biopsies are increasingly being performed in patients with advanced prostate cancer to search for actionable targets and/or to identify emerging resistance mechanisms. Due to a predominance of bone metastases and their sclerotic nature, obtaining sufficient tissue for clinical and genomic studies is challenging. METHODS: Patients with prostate cancer bone metastases were enrolled between February 2013 and March 2017 on an institutional review board-approved protocol for prospective image-guided bone biopsy. Bone biopsies and blood clots were collected fresh. Compact bone was subjected to formalin with a decalcifying agent for diagnosis; bone marrow and blood clots were frozen in optimum cutting temperature formulation for next-generation sequencing. Frozen slides were cut from optimum cutting temperature cryomolds and evaluated for tumor histology and purity. Tissue was macrodissected for DNA and RNA extraction, and whole-exome sequencing and RNA sequencing were performed. RESULTS: Seventy bone biopsies from 64 patients were performed. Diagnostic material confirming prostate cancer was successful in 60 of 70 cases (85.7%). The median DNA/RNA yield was 25.5 ng/µL and 16.2 ng/µL, respectively. Whole-exome sequencing was performed successfully in 49 of 60 cases (81.7%), with additional RNA sequencing performed in 20 of 60 cases (33.3%). Recurrent alterations were as expected, including those involving the AR, PTEN, TP53, BRCA2, and SPOP genes. CONCLUSIONS: This prostate cancer bone biopsy protocol ensures a valuable source for high-quality DNA and RNA for tumor sequencing and may be used to detect actionable alterations and resistance mechanisms in patients with bone metastases. Cancer 2018;124:1008-15. © 2017 American Cancer Society.


Subject(s)
Bone Neoplasms/secondary , Bone and Bones/pathology , Prostate/pathology , Prostatic Neoplasms/pathology , Aged , Aged, 80 and over , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/genetics , Bone and Bones/diagnostic imaging , Bone and Bones/metabolism , High-Throughput Nucleotide Sequencing/methods , Humans , Image-Guided Biopsy , Magnetic Resonance Imaging/methods , Male , Middle Aged , Positron-Emission Tomography/methods , Precision Medicine/methods , Prospective Studies , Prostate/diagnostic imaging , Prostate/metabolism , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/genetics
14.
Curr Urol Rep ; 15(6): 414, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24740274

ABSTRACT

Renal artery stenosis resulting in renovascular hypertension or renal ischemia is a potentially treatable condition that results in increased morbidity and mortality, especially among older individuals. Sophisticated imaging techniques are used for screening and identification of affected patients to guide therapy. Treatment guidelines recommend intervention in patients with significant renal artery stenosis, although recent evidence has questioned the benefit of intervention in certain populations. Current research focuses on improving the specificity of imaging techniques and determining which imaging modalities best identify patients who will benefit from intervention.


Subject(s)
Angioplasty/methods , Renal Artery Obstruction , Renal Artery , Angiography , Humans , Hypertension, Renovascular/diagnosis , Hypertension, Renovascular/etiology , Hypertension, Renovascular/therapy , Magnetic Resonance Angiography/methods , Magnetic Resonance Imaging, Interventional/methods , Mass Screening , Radiography, Interventional/methods , Radionuclide Imaging , Renal Artery/diagnostic imaging , Renal Artery/innervation , Renal Artery Obstruction/complications , Renal Artery Obstruction/diagnosis , Renal Artery Obstruction/therapy , Stents , Sympathectomy/methods , Tomography, X-Ray Computed , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...